Moderna (MRNA) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Moderna (MRNA) last issued guidance on July 31, 2026 for fiscal year 2026. The company guided revenue in the range of $2.14B - $2.14B for the period.
Compared to prior guidance, Moderna maintained its revenue forecast from a prior range of $2.14B - $2.14B.
Moderna has issued 13 guidance updates between November 2, 2023 and July 31, 2026. During this period, the company raised its outlook 2 times and lowered it 4 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-2.07 | $-3.71 | $-2.60 | $-2.17 |
| Actual | $-1.97 | $-1.18 | $-2.11 | $-0.51 |
| Surprise | +4.83% | +68.2% | +18.9% | +76.5% |
| Revenue | ||||
| Estimate | $104.4M | $233.8M | $638.9M | $866.0M |
| Actual | $145.0M | $389.0M | $678.0M | $1.02B |
| Surprise | +38.9% | +66.4% | +6.12% | +17.3% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-1.37 | $-1.86 | $-2.20 | $-2.16 |
| Revenue | ||||
| Consensus | $882.4M | $690.6M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Jul 31, 2026 | $-1.97 | $-2.07 | 4.83 % |
| Q1 | May 1, 2026 | $-1.18 | $-3.71 | 68.2 % |
| Q4 | Feb 13, 2026 | $-2.11 | $-2.60 | 18.9 % |
| Q3 | Nov 6, 2025 | $-0.51 | $-2.17 | 76.5 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Jul 31, 2026 | $145.00M | $104.40M | 38.9 % |
| Q1 | May 1, 2026 | $389.00M | $233.79M | 66.4 % |
| Q4 | Feb 13, 2026 | $678.00M | $638.92M | 6.12 % |
| Q3 | Nov 6, 2025 | $1.02B | $865.96M | 17.3 % |